@dliftstok's IGF1-LR3 reconstitution tutorial fact-checked

What did @dliftstok actually say?

The creator walked through reconstituting IGF-1 LR3, a synthetic analog of insulin-like growth factor 1, using a 1:1 ratio of bacteriostatic water and acetic acid, one milliliter of each, to dissolve one milligram of peptide. The stated goal was preventing the gelation that reportedly plagues this compound. They demonstrated syringe technique, alcohol-wiping stoppers, and slow injection into the vial to avoid pressure buildup. They also noted that AOD-9604 gels similarly, and mentioned anecdotal reports of the same issue with TB-500, though they said they had not personally experienced it.

To their credit, they framed the video as educational, not as medical advice, and they referenced third-party batch testing from their supplier, Alpha Omega. That kind of sourcing transparency is rare in peptide content and worth acknowledging.

Does the science back this up?

The acetic acid reconstitution approach is biochemically defensible, but the specific ratio used here is not validated by any published clinical protocol. IGF-1 LR3 is a research-grade compound, not an approved pharmaceutical, so there are no peer-reviewed reconstitution guidelines to cite. What we do know from peptide chemistry literature supports the general logic.

IGF-1 LR3 has an isoelectric point around pH 5.5, meaning it is more stable and soluble in mildly acidic conditions. Dilute acetic acid, typically 0.1% to 1%, is a standard solvent used in research settings for acidic peptides precisely because it prevents aggregation and gelation. A 2014 review by Manning et al. in Pharmaceutical Research confirmed that pH management is one of the primary tools for preventing peptide aggregation during reconstitution. However, the creator does not specify the concentration of their acetic acid, which is a meaningful gap. A food-grade 5% acetic acid solution diluted 1:1 into bacteriostatic water produces a very different final pH than a research-grade 0.1% solution. That distinction matters for both peptide stability and injection safety.

What did they get wrong (or right)?

They got the core concept right: acetic acid does help prevent IGF-1 LR3 from gelling. That is consistent with published peptide formulation science. The alcohol-wiping protocol and the advice to inject slowly to reduce pressure are also sound sterile technique basics.

Here is where it breaks down. The creator says to use "one ML of each" without specifying the concentration of the acetic acid. That is a significant omission. Injecting a solution with an inappropriate acid concentration could cause local tissue irritation or, in a worse case, pH-induced cell damage at the injection site. Research on subcutaneous injections published by Berteau et al. in 2015 in the International Journal of Pharmaceutics identified local pH as a primary driver of injection-site reactions. The creator also describes this peptide casually without mentioning that IGF-1 LR3 is not approved by the FDA for human use, carries real risks including hypoglycemia and potential mitogenic effects on tissue, and is explicitly banned by WADA. Leaving that context out of a 65,000-view tutorial is a problem.

What should you actually know?

IGF-1 LR3 is not a wellness supplement. It is a potent growth factor analog with a longer half-life than endogenous IGF-1, estimated at 20 to 30 hours versus a few minutes for native IGF-1. That extended activity window is exactly why researchers study it, and exactly why unsupervised use carries real risk. Hypoglycemia is a documented concern. So is the theoretical promotion of abnormal cell growth, particularly in individuals with undiagnosed cancers or pre-cancerous tissue. A 2012 meta-analysis by Renehan et al. in The Lancet Oncology found significant associations between elevated circulating IGF-1 levels and increased risk of several cancers. Using an exogenous analog that amplifies IGF-1 signaling without medical supervision is not a trivial decision.

On the practical chemistry side: if you encounter guidance to use acetic acid for reconstitution, the concentration matters enormously. Research-grade protocols typically specify 0.1% glacial acetic acid, not undiluted household or supplement-grade product. Batch testing from a supplier, as the creator referenced, addresses identity and purity but does not validate the reconstitution method or the safety of the final solution for human injection.

Bottom line

This video offers technically plausible advice about a real problem with IGF-1 LR3 gelation, but it skips the information that would allow someone to actually assess the risk of what they are doing. The acetic acid strategy has scientific grounding. The execution details, particularly acid concentration, are dangerously vague. And no reconstitution tutorial for a non-approved, WADA-banned compound with known mitogenic potential is complete without a frank discussion of what that compound actually does in the body.